Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Human papillomavirus genotype-specific risks for cervical intraepithelial lesions

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Cutaneous necrotic ulceration due to BCG re-vaccination

    Research output: Contribution to journalJournal articleResearch

  1. Expanding our understanding of ovarian cancer risk: the role of incomplete pregnancies

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Borderline ovarian tumors in Denmark 1997-2018: Time trends in incidence by histology, age and educational level

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Low-dose aspirin use and risk of head and neck cancer-A Danish nationwide case-control study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Endometrial cancer risk after fertility treatment: a population-based cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Mari Nygård
  • Bo T Hansen
  • Susanne K Kjaer
  • Maria Hortlund
  • Laufey Tryggvadóttir
  • Christian Munk
  • Camilla Lagheden
  • Lara G Sigurdardottir
  • Suzanne Campbell
  • Kai-Li Liaw
  • Joakim Dillner
View graph of relations

Prevalence of different HPV genotypes is changing after HPV vaccination. The associated risks are needed for optimizing cervical cancer screening. To estimate HPV type-specific prevalence, odds ratio (OR), and positive predictive value (PPV) for cervical cytological abnormalities, we determined 41 different HPV genotypes in cervical samples from a population-based sample of 8351 women aged 18-51 years before HPV vaccination era (V501-033; NCT01077856). Prevalence of HPV16 was 4.9% (95% CI: 4.4-5.5) with the PPV for high-grade cytology 11.2%, and OR 11.9 (95% CI: 8.5-16.5). Carcinogenic HPVs included in the nonavalent vaccine (HPV16,18,31,33,45,52,58) had a population prevalence of 14.4% (95% CI: 13.5-15.4), with PPV of 8.0% (95% CI: 6.8-9.3) and OR 23.7 (95% CI: 16.0-63.5) for high-grade cytology. HPV types currently included in most screening tests, but not vaccinated against (HPV35,39,51,56,59,66,68) had a joint prevalence of 8.5% (95% CI: 7.8-9.2) with PPV of 4.4% (95% CI: 3.3-5.7) and OR of 2.9 (95% CI: 2.0-4.0) for high-grade cytology. The other 27 non-carcinogenic genotypes had a prevalence of 11.8%, PPV of 2.9% (95% CI:2.1-3.9), and OR 1.5 (95% CI: 1.1-2.2.) for high-grade cytology. These results suggest that HPV screening tests in the post-vaccination era might perform better if restricted to the HPV types in the nonavalent vaccine and screening for all 14 HPV types might result in suboptimal balance of harms and benefits.

Original languageEnglish
JournalHuman vaccines & immunotherapeutics
Volume17
Issue number4
Pages (from-to)972-981
Number of pages10
ISSN2164-5515
DOIs
Publication statusPublished - 3 Apr 2021

    Research areas

  • Denmark, high-risk HPV, Iceland, liquid-based cytology, low-risk HPV, Norway, population-based prevalence, Sweden

ID: 61555505